skip to Main Content

Trial Testing EDV Nanocells in Pancreatic, Other EGFR-positive Advanced Solid Cancers Now Dosing Patients

Newsfeed image, light gray text on dark gray background
A Phase 1/2 clinical trial has started dosing participants to test EnGeneIC‘s second-generation cytotoxic-loaded EDV nanocells as a treatment for EGFR-positive solid cancers who have exhausted all other therapeutic alternatives.

The Carolyn Trial (ACTRN12619000385145), still recruiting participants at the Frankston Private Hospital in Victoria, Australia, is expected to include 40 patients with advanced pancreatic cancer, and an additional 40 with other EGFR-positive tumors. Read more . . . 

Back To Top